GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.Ultragenyx Faces Class Action Over Failed Drug Trials; April 6 Lead Plaintiff Deadline Looms
Ultragenyx faces class action lawsuit over misleading statements on setrusumab efficacy. Stock crashed 42% after Phase III trials failed. Lead plaintiff deadline: April 6, 2026.
RAREsecurities fraudclass action lawsuit